Journal of Labelled Compounds and Radiopharmaceuticals—Vol.XXXII

NINTH INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL CHEMISTRY

Paris, 6 –10 April 1992

CONTENTS

LUNDI 6 AVRIL 1992 / *MONDAY 6th APRIL 1992*

9:00 - 9:15 Allocution de bienvenue / *Opening Remarks*
D. COMAR Président / *Chairman*

9:15 - 9:30 Allocution par Monsieur le Haut Commissaire à l'Energie Atomique

A - CHIMIE DU TECHNETIUM / *TECHNETIUM CHEMISTRY*

Présidents de séance / *Chairpersons:* A. JONES - A. VERBRUGGEN

11:00 - 12:30 **Présentations orales / *Oral presentations*** **Page**

A1 Synthesis and characterization of oxotechnetium complexes with tripodal ligands. 1
Mastrostamatis S., Papadopoulos M., Psilla M., Stassinopoulou C., Varvarigou A., Chiotellis E.

A2 Tc-PnAO complexes that are substituted at the central carbon atom. 4
Cyr J., Linder K.E., Nanjappan P., Raju N., Ramalingam K., Nowotnik D.P., Nunn A.D.

A3 PN-bidentate and P_2N_2-tetradentate amino-phosphine ligands suitable for MO^{3+} (M=Tc, Re) coordination. 7
Refosco F., Bolzati C., Bandoli G., Moresco A., Nicolini M., Tisato F.

A4 Studies of formation of the Tc=N bond from the reaction of $[^{99m}TcO4]^-$ with different $N3^-$ donor ligands. 10
Comazzi V., Ucelli L, Bellande E., Duatti A., Pasqualini R., Marchi A.

A5 The characterization and synthesis of Technetium complexes which contain organonitrogen cores from pertechnetate. 12
Nicholson T., Davison A., Jones A.G.

A6 The synthesis of Nitroimidazole bato (Boronic acid Adducts of Technetium Dioxime) derivatives and their in-vitro evaluation as potential hypoxia imaging radiophamaceuticals. 13
Linder K.E., Raju N., Cyr J., Chan Y.W., Ramalingam K., Nowotnik D.P., Nunn A.D.

A7 A new and versatile multifunctional phosphorus hydrazide ligand for formulating neutral-lipophilic complexes of ^{99m}Tc, ^{186}Re and ^{109}Pd radionuclides. 15
Volkert W.A., Singh P.R., Katti K.K., Ketring A.R., Katti K.V.

A8 New Technetium complexes with P_2 and P_3 ligands. 18
Marchi A., Marvelli L., Rossi R., Uccelli L., Magon L.

A9 Quantitative study of the structure-stability of TcO(III)-complexes based on CNDO/2 method. 21
Liu B.L., Meng Z.X., Kung H.F.

A10 Kinetic and thermodynamic stabilities of TcO_2-OXO and DIOXO cyclams. 24
Riche F., Trimcev I., Godart J., Benabed A., Comet M., Duatti A., Pasqualini R., Vidal M.

Présentation des affiches / *Poster presentation*

A11 Tc-99m U-BAT: a case of BAT (N_2S_2) ligand with uneven amines. 26
Kung H.F., Francesconi L.C., Yang Y.Y., Kung M.P., Billings J., Guo Y.Z., Zhang X.X.

A12 Evaluation of insoluble macromolecular Sn(II) complexes for preparation of ^{99m}Tc radiopharmaceuticals. 29
Nakayama M., Terahara T., Wada M., Koiso T., Araki N., Harada K., Sugii A.

A13 The determination of charge of Technetium complexes by ion exchange HPLC. 31
Nowotnik D.P., Riley A.L.M.

A14 Electronic structure of D,l- and meso-isomeric forms of TcO(HM-PAO) complexes and radioanalytical composition of corresponding radiopharmaceutical preparation. 34
Khleskov V.I., Smirnov A.B., Nikitin S.M., Bychkova E.B., Nikitina A.V., Petrova T.V.

A15 Application of NMR and Moessbauer spectroscopy for the development of ^{99m}Tc - radiopharmaceuticals. 35
Sergeev V., Babushkina T., Kodina G.

A16 Characterization of Technetium-99 complexes with S-unprotected mercaptoacetylpeptides (MAG_3, MAG_2, MAG_1 and derivatives). 37
Johannsen B., Noll B., Noll St., Spies H.

A17 Structure and activity of Technetium (V) diphosphine complexes. 40
Kelly J.D., Higley B., Archer C.M., Canning L.R., Chiu K.W., Edwards B., Forster A.M., Gill H.K., Latham I.A., Pickett R.D., Edwards P.G., Imran A.

A18 Potentiometric and spectrophotometric study of ^{99}Tc-DPD complexes. 42
Razumenio N., Veselinovio D., Nikolio V.

A19 Technetium (V) complexes with schiff base ligands containing the Onssno donor atom set. 45
Psilla M., Papadopoulos M., Mastrostamatis S., Maina Th., Mikros M., Stassinopoulou C., Chiotellis E.

A20 Reaction and storage temperature effects on the proportion of lipophilic and hydrophilic complexes of [^{99m}Tc]HMPAO. 47
Billinghurst M.W., Abrams D.N., Shyka C., Vaziri F.

14:00 - 15:00 Conférence / *Invited lecture :*
Apport des méthodes d'imagerie à l'étude du fonctionnement cérébral et cardiaque chez l'homme / *Complementarity of noninvasive imaging techniques for the investigation of the living brain and heart.*
A. SYROTA - Professeur de Biophysique et Médecine Nucléaire à l'Université Paris XI, Chef du Département de Recherches en Imagerie, Pharmacologie et Physiologie au Commissariat à l'Energie Atomique.

B - PRODUITS RADIOPHARMACEUTIQUES TECHNETIES / *TECHNETIUM RADIOPHARMACEUTICALS*

Présidents de séance / *Chairpersons:* J.R. THORNBACK - S.C. SRIVASTAVA

16:00 - 17:30 **Présentations orales / *Oral presentations***

B1 Technetium-99m complexes of 3-hydroxy-4-pyridinone ligands. 50
Edwards D.S., Poirier M.J., Orvig C.

B2 Preparation and biodistribution in rats of bis(dithiocarbamato) nitrido Technetium (V) radiopharmaceuticals: influence of ligand side chains on heart uptake. 53
Bellande E., Brucato V., Comazzi V., Lainé V., Lecayon M., Duatti A., Pasqualini R.

B3 Synthesis of Technetium nitrido radiopharmaceuticals with HMPAO. 55
Uccelli L., Duatti A., Pasqualini R., Giganti M., Piffanelli A., Magon L.

B4 A new Tc-99m labeled brain scanning agent with elimination of chiral centers in the coordination sphere with a compact nine-member core. 57
Dewanjee M.K., Ghafouripour A.K., Ganz W.I., Serafini A.N., Sfakianakis G.N.

B5 Synthesis and biological evaluation of dicarboxylate Technetium-99mdiamide-dimercaptide complexes as potential renal imaging agents. 59
Canney D.J., Billings J.J., Guo Y.Z., Francesconi L.C., Kung H.F.

B6 Synthesis and biological studies of a new renal function agent: 62
[hexakis(carboxymethylisocyanide)Technetium]$^{+5}$.
Kronauge J.F., Barbarics E., Davison A., Jones A.G.

B7 A reduction of pI prevents kidney uptake of avidine. 65
Jeong J.M., Kinuya S., Paik C.H., Saga T., Sood V.K., Neumann R.D., Reynolds J.C., Carrasquillo J.A.

B8 Technetium-99m-labeled chemotactic peptides via the hydrazino nicotinamide derivative for imaging focal sites of infection. 68
Babich J.W., Abrams M.J., Schwartz D., Kroon D., Pike M., Strauss H.W., Rubin R.H., Fischman A.J.

B9 Syntheses of QNB boronic acid stereoisomers and their BATO complexes: potential ^{99m}Tc mACh receptor binding tracers. 69
Nanjappan P., Ramalingam K., Jurisson S., Pirro J., Di Rocco R., Narra R.K., Nowotnik D.P., Nunn A.D.

Présentation des affiches / *Poster Presentation*

B10 Synthesis and Technetium-99m labelling of 2-alkoxyisobutylisonitrile. 72
Lee T.W., Su C.S., Shen L.H., Ting G.

B11 Convenient synthesis of analogs of N-(S-benzoylmercaptoacetyl) glycylglycylglycine. 74
Yang C.H., Chen C.C., Chen M.K., Ting G., Lee T.W.

B12 Preparation of ^{99m}Tc-labelled d, 1-diastereoisomer of HM-PAO for cerebral blood flow imaging. 76
Bai L., Huang J., Bai S., Xiao L.

B13 Optimum synthesis condition for Technetium-99m labelled DTPA-HSA and its behaviour. 78
Tang H., Ding J.H., Lin Q.F., Fan G.Y., Bai L.Q.

B14 Synthesis of Tc-99m labelled ranitidine. 81
Du J., Jin X.H., Yaun S.Y.

B15 Effect of stereoisomers (D,L and Meso) of Tc-99m HMPAO on platelet labeling and kinetics in beagle dogs: comparison with In-111 labeled platelets. 83
Dewanjee M.K., Ghafouripour A.K., Kapadvanjwala M., Ganz W.I., Serafini A.N., Sfakianakis G.N.

B16 Liver cancer imaging agent ^{99m}Tc-N-pyridoxyl-5-methyltryptophan (^{99m}Tc-5-PMT) derivatives ^{99m}Tc-6-PMT and ^{99m}Tc-7-PMT syntheses and biodistributions. 85
Zhou Y.G., Xiao Z.L., Chen J.Z.

B17 Synthesis, characterization and biodistribution of new ^{99m}Tc nitrido complexes with unsatured N_2S_2 schiff base. 87
Coulais Y., Guiraud R., Gros G., Darbieu M.H., Pasqualini R.

B18 Synthesis of a Tc-99m MAG3-biotin conjugate as a biliary agent. 88
Jeong J.M., Kinuya S., Paik C.H., Saga T., Sood V.K., Neumann R.C., Reynolds J.C., Carrasquillo J.A.

B19 TcO^{3-} and TcN^{2+} cores complexation by dithioetherdithiols biodistribution in mice. 91
Drouillard S., Alagui A., Apparu M., Comet M., Pasqualini R., Vidal M.

B20 Tc-99m and In-113m complexes with DTPA diamides; biodistribution of Tc-99m-DTPA(NH-HIPP)$_2$. 93
Brattsev V.A., Milovskaya I.N., Terentyeva E.A., Arkhapchev Yu.P.

B21 Synthesis, labeling with Tc-99m and biological evaluation of new ligands related to both MAG_3 and Hippuric acid. 94
Stepniac-Biniakiewicz D., Vavouraki H., Mastrostamatis S., Chiotellis E., Deutsch E.

B22 **PAPER WITHDRAWN** 96

MARDI 7 AVRIL 1992 / *TUESDAY 7th APRIL 1992*

C - CHIMIE ORGANIQUE AVEC ^{18}F / *^{18}F ORGANIC CHEMISTRY*

Présidents de séance / *Chairpersons:* M. KILBOURN - H.H. COENEN

9:00 - 10:30 **Présentations orales / *Oral presentations***

C1 Can we predict reactivity for aromatic nucleophilic substitution with [^{18}F]Fluoride ? 99
Rengan R., Kilbourn M.R.

C2 Production optimization of a bifunctional fluorine-18 labeled radiopharmaceutical intermediate: 101
Fluorine-18 Fluoroacetophenone.
Banks W.R., Hwang D.R., Borchert R.D., Mantil J.C.

C3 [^{18}F]Fluorination of 3-pyrrolidinol. A comparison of relative [^{18}F]fluorination rate of sulfonic 104
esters of 3-pyrrolidinol and the unexpected [^{18}F]labeling of tresylate.
Hwang D.R., Banks W.R., Borchet R., Mantil J.C.

C4 A novel, metabolically stable site for Fluorine-18 labeling of progestins, useful in the development 106
of imaging agents for Progesterone receptor-positive breast tumors.
VanBrocklin H.F., Kym P.R., O'Neil J.P., Bonasera T.A., Welch M.J., Katzenenellenbogen J.A.

C5 [^{18}F]Fluoroacetic acid and [2-^{18}F]Fluoropropionic acid derivatives as reactive fluoroacylation agents. 108
Guhlke S., Coenen H.H., Stöcklin G.

C6 N.C.A.-[^{18}F]-Fluorination of aromatic compounds by fluorodediazonisation. 111
Knöchel A., Zwernemann O.

C7 Preparation of no-carrier-added N-([^{18}F]4-fluorophenyl)piperazine. 112
Collins M., Lasne M.C., Barré L., Baron J.C.

C8 Non-activated ^{18}F-fluorinated aromatic compounds through nucleophilic substitution and decarbonylation 114
reactions using $RhCl[P(C_6H_5)_3]_3$.
Plenevaux A., Lemaire C., Palmer A.J., Damhaut P., Comar D.

C9 Synthesis and evaluation of 2-Deoxy-2-[^{18}F]-Fluoro-ß-Mannosyl fluoride as a mechanism-basedimaging 116
probe for glycosidase enzymes.
Adam M.J., McCarter J.D., Withers S.G.

C10 Selective recovery of usable quantities of [^{18}F]fluoride and [^{13}N]nitrate/nitrite for FDG and ammonia 118
synthesis from a single irradiation of low-enriched [^{18}O]water.
Ferrieri R.A., Schyler D.J., Shea C., Wolf A.P.

Présentation des affiches / *Poster Presentation*

C11 Fluorine-18 derivatives of 7-Chloro-8-Hydroxy-3-Methyl-1-(3'-Aminophenyl)-2,3,4,5-Tetrahydro-1H-3-Benzazepine(SCH 38548): Selective and high affinity fluorinated radioligands for dopamine D-1 receptors. 120
Mukherjee J., Yang Z.Y., Perry B., Cooper M.

C12 Synthesis of 2-[^{18}F]FDG using microwave radiation. 123
Chirakal R., Girard L., Firnau G., Garnett E.S.

C13 The effect of acetonitrile and inert atmosphere on ^{18}F-Fluoride ion exchange reaction. 125
Najafi A., Peterson A.

C14 Preparation and in vitro evaluation of ^{18}F labeled biotin. 128
Najafi A., Peterson A.

C15 Observations and strategies to reduce gaseous emissions during 2-[^{18}F]Fluoro-2-Deoxyglucose synthesis. 131
Watkins G.L., Richmond J.C.W., Boles Ponto L.L., Hichwa R.D.

C16 Optimization studies concerning the direct nucleophilic fluorination of Butyrophenone neuroleptics. 132
Katsifis A., Hamacher K., Schnitter J., Stöcklin G.

C17 Rapid synthesis of Fluorine-18 labelled Benzhydrols, high specific activity intermediates for use in syntheses of [^{18}F]-1,4-Benzodiazepine-2-ones. 134
Johnström P., Stone-Elander S.

C18 Drug substance determination in 2-Deoxy-2-[^{18}F]Fluoro-D-Glucose preparations. Comments on the purity of ^{18}F-labelled 2-Deoxy-2-Fluoro-D-Glucose. 135
Oberdorfer F., Weber K., Haberkorn U., Gottschall K., Maier-Borst W.

C19 Synthesis of [^{18}F]F_2 from [^{18}F]F^-(aq). 137
Solin O., Aho K., Bergman J., Källman K.M., Oakes T.R.

C20 NCA Asymmetric synthesis of 2-[^{18}F]Fluoro-L-tyrosine. 139
Lemaire C., Plenevaux A., Damhaut P., Guillaume M., Christiaens L., Comar D.

C21 1-[^{18}F]Fluoro-2-propanol *p*-toluenesulfonate: a synthon for the preparation of N-([^{18}F]Fluoroisopropyl) amines. 141
De Groot T.J., Elsinga P.H., Visser G.M., Vaalburg W.

C22 Synthesis and evaluation of ^{18}F-labelled biotin derivatives for tumor localization with PET. 142
Shoup T.M., Elmaleh D.R., Fischman A.J., Strauss H.W.

C23 Experiences with the solid phase supported nucleophilic substitution approach in the preparation of 2-Deoxy-2-[^{18}F]Fluoro-D-Glucose using a computer assisted remote controlled system. 144
Dietrich-Wolber S., Knigge H., Obers W.J., Oberdorfer F., Maier-Borst W.

C24 Synthesis of Fluorine-18 Lomefloxacin, a fluorinated quinoline antibiotic. 145
Tewson T.J.

D - CHIMIE ORGANIQUE AVEC ^{11}C ET ^{13}N / *^{11}C AND ^{13}N ORGANIC CHEMISTRY*

Présidents de séance / *Chairpersons:* B. LANGSTRÖM - G. KABALKA

11:30 - 13:00 **Présentations orales / *Oral Presentations***

D1 Investigation of possible routes to [^{11}C]Methyl triflate. 147
Jewett D., Mulholland K.

D2 On-line N-[^{11}C]methylation by [^{11}C]Methyl iodide. 148
Iwata R., Pascali C., Yuasa M., Yanai K., Takahashi T., Ido T.

D3 Synthesis of [O-Methyl-^{11}C]-2-methoxyethanol by solid phase catalysed addition of N.C.A. [^{11}C]methanol to oxirane. 150
Bender D., Hamacher K., Stöcklin G.

D4 Synthesis of [^{11}C]Methylisocyanate. Application to the labelling of a potent acetylcholinesterase inhibitor: [^{11}C]Physostigmine. 152
Bonnot Lours S., Prenant C., Crouzel C.

D5 Microwave cavity: use in ^{11}C-alkylations. 154
Stone-Elander S., Elander N.

D6 Asymmetric synthesis of n.c.a. L-[2-^{11}C]-4-chlorophenylalanine. 156
Plenevaux A., Al-Darwich M.J., Lemaire C., Delfiore G., Christiaens L., Comar D.

D7 Synthesis of [^{11}C]CGP 20712A: A selective beta-1 adrenoceptor ligand for PET. 158
Elsinga P.H., Van Waarde A., Visser G.M., Vaalburg W.

D8 Simplified asymmetric synthesis and chiral analysis for S-[*Carbonyl*-^{11}C]CGP 12177 production. 159
Aigbirhio F., Pike V.W., Francotte E., Jaeggi K., Waters S.L.

D9 A microprocessor-controlled system for the production of multiple batches of Oxygen-15 labeled Butanol. 162
Moerlein S.M., Gaehle G.G., Lechner K.R., Bera R.K., Welch M.J.

D10 Synthesis of Nitrogen-13 labeled amines using organoborane polymers. 165
Kabalka G.W., Goodman M.M., Green J.F., Marks R., Longford D.

Présentation des affiches / *Poster presentation*

D11 Syntheses of homochiral ^{11}C-labelled radioligands for peripheral benzodiazepine binding sites. 166
Shah F., Pike V.W., Turton D.R.

D12 The production of ^{11}C-Iomazenil. 169
Westera G., Eberle I., Hunkeler W., Ametamey S., Schubiger P.A.

D13 Preparation of Nitrogen-13 labelled polypeptides for positron-emission tomography. 171
Landais P., Waltz P., Tochon-Danguy H., Goethals P., Strijckmans K., Rose K., Offord R.E.

D14 Syntheses of [^{11}C]Epinephrine and other biogenic amines by direct methylation of normethyl precursors. 172
Chakraborty P.K., Gildersleeve D.L., Toorongian S.A., Kilbourn M.R., Schwaiger M., Wieland D.M.

D15 Remote system for the routine production of [^{11}C]-Methyl albumin. Application to pulmonary studies. 174
Dence C.S., Lechner K.R., Welch M.J.

D16 Specific activity of ^{11}C-CO_2 determined by reaction with tritylllithium yielding ^{11}C-Triphenylacetic acid. 176
Schmall B., Simpson N.R., Eckelman W.C.

D17 Synthesis of 2-[^{11}C]Thymine from [^{11}C]Phosgene: a precursor for 2-[^{11}C]Thymidine. 178
Steel C.J., Brown G.D., Dowsett K., Turton D.R., Luthra S.K., Tochon-Danguy H., Waters S.L., Price P., Brady F.

D18 No carrier added [^{11}C]Allylation of amines. 180
Lasne M.C., Moreau B., Barré L., Cairon Ph., Ducandas C.

D19 A modified preparation method for ^{11}C -Acetate, preventing liquid phase extraction steps. 182
Meyer G.J., Günther K., Matzke K.H., Harms Th., Hundeshagen H.

D20 A robot-based system for the development of production methods for radiotracers for PET. 184
Appelqvist G., Bohm C., Eriksson H., Stone-Elander S.

D21 Radiomethylation of Ethyl Acetoacetate and its use as an intermediate for some ^{11}C-radiopharmaceuticals. 185
Ogawa K., Nozaki T.

D22 The synthesis and labeling of [^{11}C]-N-Methyl and Ethyl nor-Fenfluoramine as serotonin ligands for PET. 187
Meng X., Wurtman R.J., Shoup T.M., Jones A.J., Davison A., Kizuka H., Strauss H.W., Fischman A.J., Elmaleh D.R.

D23 [O-Methyl-^{11}C]Nimodipine: a high yield, one pot synthesis. 189
Holschbach M., Coenen H.H., Schüller M., Goldmann S., Stöcklin G.

D24 The routine synthesis of Carbon-11 Phosgene, an intermediate to Carbon-11 2-Thymine. 191
Dobbs F.R., Franceschini M., Tewson T.J.

E - HALOGENES / *HEAVY HALOGENS*

Présidents de séance / *Chairpersons:* W.C. ECKELMAN - B. MAZIERE

16:00 - 17:30 **Présentations orales / *Oral presentations***

E1 Optimal yields for the Cu^{1+} assisted radiohalogenation by respecting the mechanistic parameters. 195
Gysemans M., Mertens J.

E2 Polymer-bound radiopharmaceuticals: N-Isopropyl-4-Iodoamphetamine. 196
Culbert P., Hunter D.

E3 Monoamine storage site imaging agent for SPECT: Iodinated Tetrabenazine. 199
Canney D., Kung M.P., Guo Y.Z., Kung H.F.

E4 The synthesis of radioiodinated vinyl iodides via organoborane chemistry. 201
Kabalka G.W., Goodman M.M., Maddox J.T.

E5 Radioiodinated Clorgyline derivative for mapping MAO-A activity in brain with SPECT. 204
Hirata M., Ohmomo Y., Magata Y., Saji H., Tanaka C., Kung H.F., Yokoyama A.

E6 Use of aryltin substrates for high specific activity radiohalogenation of amine derivatives. 207
Application to labeling of amphetamine, phentermine and benzamide derivatives.
Dao-Boulanger T.H., Brucato V., Lecayon M., Mauclaire L., Moreau M.F., Pasqualini R.

E7 Synthesis of ^{125}I-p-Iodophenyltriphenylphosphonium nitrate as a tracer for malignant central 209
nervous system.
Byon C.Y., Weiss M.J., Martuza R.L., Messner E., Hanson R., Fischman A.J., Elmaleh D.R.

E8 Acylation reagents for the radiohalogenation of peptides. 212
Garg S., Garg P.K., Zalutsky M.R.

E9 Radioiodinated Corticotrophin-Releasing Factor (CRF): A potential radiopharmaceutical for 214
CRF-receptor imaging.
Babich J.W., Fischman A.J., Jyawook S., Wilkinson R., Graham W., Strauss H.W., Rubin R.

E10 Synthesis of halogenated analogues of 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a) 217
isoindole or mazindol as new dopamine uptake carrier ligands.
Galinier E., Garreau L., Frangin Y., Mertens J., Ombetta-Goka J.E., Chalon S., Besnard J.C., Guilloteau D.

Présentation des affiches / *Poster presentation*

E11 *S*-Adenosyl-*L*-Homocysteine hydrolase as a potential target for diagnosis with radiohalogenated 219
nucleosides.
Srivastava P.C., Hasan A.

E12 Design of ^{123}I production technology on IAE Cyclotron. 222
Venikov N.I., Novikov V.I., Sebiakin A.A.

E13 Fluorinated and Iodinated Dopamine Agents (FIDA): D2 Imaging agents for PET and SPECT. 223
Chumpradit S., Kung M.P., Kung H.F.

E14 Synthesis and target tissue uptake of the 7α-Methyl and 11ß-Methoxy derivatives of the 20Z and 20E isomers of 17α−[^{125}I]Iodovinyl-2- and -4-Fluoroestradiols. 225
Ali H., Rousseau J., Van Lier J.E.

E15 Radiopharmaceutical development of ^{123}I-3-Iodotyrosine (A14)-Insulin, a site-specific labeled ligand for in-vivo insulin-receptor scintigraphy. 228
Angelberger P., Buccheit O., Egger M., Portner R.

E16 Radio-embolismic therapy agent for liver cancer---A high yield radioiodination of Iophendylate. 231
Zhou Y.G., Zhong G.R., Wang P., Lu J.Z., Tang Z.Y.

E17 Excitation functions of Deuteron-induced nuclear reactions on ^{124}Xe: Production of ^{123}I. 233
Kurenkov N.V., Malinin A.B., Sebiakin A.A., Venikov N.I.

E18 Alternate syntheses of (*S*)-*N*-[(1-Ethyl-2-Pyrrolidinyl)Methyl]-3-[^{125}I]Iodo-5,6-Dimethoxysalicylamide (Ioxipride) and (*S*)-*N*-[(1-Ethyl-2-Pyrrolidinyl)Methyl]-5-[^{125}I]Iodo-2,3-Dimethoxybenzamide (Epidepride): High affinity and selective dopamine D-2 receptor radioligands. 234
Fang Y.B., Mukherjee J., Cooper M.

E19 Synthesis of Iodine-123 labeled 3-N-Alkyl-5-Iodo-2-Thienyl-Butyrophenones for SPECT analysis of dopamine receptors. 237
Goodman M.M., Kabalka G.W., Waterhouse R.N., Collier T.L.

E20 20E - and 20Z-17α - iodovinylestradiol and 20E- and 20Z- 17α - iodovinyl - 11ß methoxyestradiol: Synthesis and biological properties comparison. 240
Foulon C., Frangin Y., Besnard J.C., Guilloteau D.

E21 Labelling of Metyrapone derivatives with radioiodine in vitro and in vivo studies. 242
Yu J., Mertens J., Zolle I., Angelberger P., Guilloteau D.

E22 A solid Xenon ice target for the production of I-123. 243
Firouzbakht M.L., Schlyer D.J., Wolf A.P.

E23 Design, lipophilicity and SAR study of Metyrapone analogues potential in vivo SPECT and PET tracers. 245
Mertens J., Moereels H., Yu J., Zolle I.

E24 Radio synthesis of (I-125) of N-Iodoallyl NOR GBR12935. 246
Hanson R., Byon C., Matsushita T., Fischman A.J., Strauss H.W., Brill R., Elmaleh D.R.

MERCREDI 8 AVRIL 1992 / WEDNESDAY 8th APRIL 1992

F - PRODUITS RADIOPHARMACEUTIQUES POUR LE SYSTEME DOPAMINERGIQUE / *RADIOPHARMACEUTICALS FOR DOPAMINERGIC SYSTEM*

Présidents de séance / *Chairpersons:* T. IDO - A. LUXEN

9:00 - 10:30 **Présentations orales / *Oral presentations***

F1 A remotely-operated system for routine production of regioselective no-carrier-added 6-[^{18}F]Fluorodopa. 248
Reddy G., Haeberle M., Beer H.F., Schubiger A.

F2 Removal of mercury contamination from 6-F-DOPA preparations. 250
Wagner R.

F3 [^{11}C]Cocaethylene: Synthesis and assessment of its bioavailability relative to cocaine. 251
Fowler J.S., Volkow N.D., MacGregor R.R., Logan J., Dewey S.L., Gatley S.J., Wolf A.P.

F4 Synthesis of no carrier added [^{18}F] GBR 12936 *via* a Wittig reaction for use in the dopamine reuptake site study. 253
Piarraud A., Lasne M.C., Barré L., Vaugeois J.M., Lancelot J.C.

F5 Synthesis of [^{18}F]-3-Fluoromethyl-N-[1-(2-Benzothienyl)-Cyclohexyl]-piperidine, a potent radioligand for the dopamine re-uptake complex. 255
Ponchant M., Crouzel C., Kamenka J.M., Hantraye Ph.

F6 Synthesis of [^{11}C]Tetrabenazine and a [^{11}C]Methoxy derivative ofα-Dihydrotetrabenazine for PET imaging of monoaminergic nerve terminals. 257
DaSilva J.N., Kilbourn M.R., Mangner T.J., Toorongian S.A.

F7 Synthesis of [F-18]-Labelled α-Fluoromethyl-p-Tyrosine, a tyrosine hydroxylase-activated decarboxylase suicide inhibitor with potential as imaging agent for dopamine nerve terminals. 260
DeJesus O.T., Murali D., Oakes T.R., Holden J.E., Nickles R.J.

F8 Structurally modified analogs of Clebopride and BRL 34778 as potential ^{18}F-labeled ligands for PET studies of the dopamine D_2 receptor. 262
Mach R.H., Nowak P.A., Luedtke R.R., Elder S.T., Jackson J.R., Hoffman P.A., Evora P.H., Molinoff P.B., Scripko J.G., Ehrenkaufer R.L.

F9 Preparation of two potent and selective dopamine D-2 receptor agonists: (R)-[propyl-^{11}C]-2-OH-NPA and (R)-[methyl-^{11}C]-2-OCH_3-NPA. 265
Halldin C., Swahn C.G., Neumeyer J.L., Hall H., Gao Y., Karlsson P., Farde L.

F10 The radiolabelling of [^{18}F]-Fluoralkylnorapomorphines via sodium iodide induced nucleophilic substitution reactions in microwave ovens. 267
Zijlstra S., De Groot T.J., Visser G.M., Vaalburg W.

Présentation des affiches / *Poster presentation*

F11 Synthesis of [^{18}F]-*o*-Fluoromethyl MPTP. 269
Berridge M.S., Sayre L.M., Arora P.K., Terris A.H., Riachi N.J., Harik S.I.

F12 Radiofluorinated analogues of Benperidol for PET study of dopaminergic D-2 receptor binding in vivo. 272
Moerlein S.M., Perlmutter J.S., Banks W.R., Parkinson D.

F13 [^{18}F]F_2 from ^{18}O gas target for direct electrophilic fluorination: synthesis of 6-[^{18}F]Fluorodopamine. 275
Chirakal R., Firnau G., Moore W., Nahmias C., Coates G., Garnett E.S.

F14 Radiolabeled analogs of cocaine as tracers for studying the dopamine transporter using PET. 277
Dannals R.F., Carroll F.I., Ravert H.T., Scheffel U., Wagner H.N., Kuhar M.J.

F15 Some things to consider when preparing 6-[^{18}F]FDOPA by radiofluorodemercuration. 279
Adams H.R., Channing M.A., Eckelman W.C.

F16 Preparation of two highly potent and selective dopamine D-2 receptor antagonists for PET: [^{18}F]NCQ 616 and [^{11}C]FLB 457. 282
Halldin C., Högberg T., Hall H., Karlsson P., Hagberg C.E., Ström P., Farde L.

F17 A rapid and efficient HPLC-method for determination of ligand metabolism during PET-studies - examplified with [^{11}C]Raclopride. 284
Swahn C.G., Halldin C., Lundström J., Erixson E., Farde L.

F18 Synthesis of carbon-11 labeled (1R-2-EXO-3-EXO)-2-Carbomethoxy-8-Methyl-8-Azabicyclo[3.2.1]Octyl-3-N-(3'-Nitrophenyl) Carbamate as a potential PET dopamine receptor imaging agent. 286
Goodman M.M., Collier T.L., Kabalka G.W., Longford C.P.D.

F19 Synthesis and C-11 labeling of some 3ß-Phenyltropane-2-Carboxylic esters (WIN) analogs for PET. 289
Elmaleh D.R., Meltzer P.C., Madras B., Liang A.Y., Brownell A.L., Hantraye P., Isacson O., Shoup T., Fischman A.J., Brownell G.L., Strauss H.W.

F20 Preparation of [76Br]-Bromotropapride, a new dopamine D2 receptor ligand for PET studies. 291
Loc'h C., Guillaume M., Stulzaft O., Cantineau R., Ottaviani M., Mazière M., Mazière B.

11:30 - 12:30 Conférence / *Invited lecture :*
Chimie supramoléculaire : principes et mise en oeuvre de la reconnaissance moléculaire / *Supramolecular Chemistry : Molecular recognition, principles and applications.*
J.M. LEHN - Prix Nobel de Chimie 1987 ; Professeur au Collège de France, Paris et à l'Université Louis Pasteur, Strasbourg.

JEUDI 9 AVRIL 1992 / *THURSDAY 9th APRIL 1992*

G - PRODUITS RADIOPHARMACEUTIQUES POUR L'ETUDE DE LA NEUROTRANSMISSION / *RADIOPHARMACEUTICALS FOR NEUROTRANSMISSION*

Présidents de séance / *Chairpersons:* G. STÖCKLIN - C. CROUZEL

9:00 - 10:30 **Présentations orales / *Oral presentations***

G1 An approach for carbon-11 labelling of cardiac receptor ligands. 293
Schoeps K.O., Nagren K., Swahn C.G., Halldin C.

G2a [^{18}F]-Fluoroacetone for radiopharmaceutical synthesis: preparation of ^{18}F-Carazolol. 296
Zheng L., Berridge M.S.

G2b Synthesis of Fluorine-18 Fluorocarazolol: a ligand for the ß-adrenergic receptor. 298
Kinsey B.M., Barber R., Tewson T.J.

G2c Synthesis of no carrier added Fluorine-18 Fluoroacetone, a useful synthetic intermediate. 300
Kinsey B., Tewson T.J.

G3 Synthesis of a PET radiotracer for studying serotonin uptake sites: [^{11}C]McN-5652-Z-68. 303
Suehiro M., Dannals R.F., Ravert H.T., Scheffel U., Wagner H.N.

G4 Synthesis of ^{18}F-labeled fluoxetine: a selective serotonin uptake inhibitor. 305
Hammadi A., Crouzel C.

G5 Cholinergic nerve markers: Benzovesamicol structural studies. 307
Jung Y.W., Van Dort M.E., Gildersleeve D.L., Kuhl D.E., Wieland D.M.

G6 The Vesamicol receptor (VR): Radioligand selectivity and the detection of central cholinergic hypofunction. 311
Efange S.M.N., Mash D.C., Basile M., Pablo J., Kung H.F., Billings J., Michelson R.H., Thomas J.R.

G7 (4)-[^{18}F]Fluoro-*tert*-Butyl Bicycloorthobenzoate (FTBOB). A potential PET tracer for the $GABA_A$ chloride channel. 313
Mulholland G.K., Kilbourn M.R.

G8 Synthesis of [^{18}F]-Fluorobepridil. A positron labeled calcium antagonist. 314
Gong J.L., Dence C.S., Welch M.J.

G9 Synthesis and evaluation of Fluorine-18 labeled benzodiazepine antagonists as PET tracers. 316
Moerlein S.M., Perlmutter J.S., Parkinson D.

G10 Strategies for labelling radiopharmaceuticals with ^{123}I. 319
Beer H.F., Bläuenstein P., Schubiger P.A.

Présentation des affiches / *Poster presentation*

G11 Radiosynthesis of 1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide: a PET tracer for $5HT_3$ receptors. 322
Chaly T., Bandyopadhyay D., Mattacchieri R., Margouleff D.

G12 Synthesis of N^1-3-[^{18}F]Fluoropropyl-N^4-2-([3,4-Dichlorophenyl]Ethyl)Piperazine, a high affinity ligand for sigma sites. 325
Kiesewetter D.O., De Costa B.

G13 Labelling of N-[^{11}C]methyl-N-diphenylbutenyl-GABA, a GABA uptake inhibitor. 327
Le Bars D., Landais P., Krogsgaard-Larsen P.

G14 A general method for preparing [^{18}F]Fluorophenethylamines. Synthesis of 4-[^{18}F]Fluorofentanyl. 328
Hwang D.R., Banks W.R., Mantil J.C.

G15 Synthesis of fluorinated Kappa opioid receptor ligands. 330
Hwang D.R., Banks W.R., Borchert R., Mantil J.C.

G16 A new approach to the production of NCA Fluorine-18 labelled butyrophenone neuroleptic agents. 333
Synthesis of γ-Iodo-p-[^{18}F]-Fluorobutyrophenone using diiodosilane.
Banks W.R., Hwang D.R., Borchert R.D., Mantil J.C.

G17 Synthesis of (+) 2-[^{11}C]Methylamino-2-Methyl-3-Phenyl-1-Propanol. A potential radiotracer for PET imaging of serotonin uptake sites. 336
DaSilva J.N., Kilbourn M.R., Mangner T.J., Toorongian S.A.

G18 Synthesis of a radiotracer for studying Sigma recognition sites using positron emission tomography: [^{11}C]L-687,384. 338
Burns H.D., Brenner N.J., Dannals R.F., Gibson R.E., Wilson A.A., Ravert H.T., Chambers M., Middlemiss D.N., Wong D.F., Wagner H.N.

G19 Evaluation of radioiodinated desmethyl diazepam as radiotracer for in vivo quantitative studies of benzodiazepine receptors. 340
Saji H., Lida Y., Nakatsuka I., Kataoka M., Yoshitake A., Yokoyama Y.

G20 Preparation of no-carrier added meta-Iodobenzylguanidine and meta-Astatobenzylguanidine. 342
Vaidyanathan G., Affleck D., Zalutsky M.R.

G21 Synthesis of a new radioligand for exploration of 5-HT re-uptake sites: 4'-[^{125}I]-Iodo-5-Methoxyvalerophenone O-(2-Aminoethyl) Oxime. 345
Frangin Y., Caillet M., Mertens J., Branger C., Ombetta J.E., Chalon S., Besnard J.C., Guilloteau D.

G22 Studies on radioiodination of MIBG in aqueous and solid phases. 347
Mansouri A., Saada B., Benzaid A.

G23 Radiosynthesis of [O-^{11}C-methyl]CP-96,345, a nonpeptide substance P (NK_1) receptor antagonist. 350
Barré L., Lasne M.C., Letessier B., Camsonne R., Baron J.C.

G24 Synthesis of a new analog of PCP: [^{18}F]-3-Fluoromethyl-TCP, a potent ligand for the NMDA glutamatergic receptor. 352
Ponchant M., Crouzel C., Kamenka J.M., Pappata S.

H - PEPTIDES, PROTEINES ET ANTICORPS / *PEPTIDES, PROTEINS AND ANTIBODIES*

Présidents de séance / *Chairpersons:* M.J. WELCH - D.M. WIELAND

11:30 - 13H00 **Présentations orales / *Oral presentations***

H1 A new reproducible method of introducing potentially metabolizable linking groups between ^{111}In-Cyclohexyl EDTA derivates and anti-CEA F(ab')$_2$ monoclonal antibody(MAb) and their evaluation in human tumor xenografted nude mice. 354
Gestin J.F., Faivre-Chauvet A., Mease R.C., Sai-Maurel C., Thedrez Ph., Slinkin M., Srivastava S.C., Chatal J.F.

H2 Effects of chelate rigidity and denticity on the in-vivo performance of ^{203}Pb and ^{88}Y labeled monoclonal antibodies. 357
Srivastava S.C., Mease R.C., Mausner L.F., Meinken G.E., Chinol M., Steplewski Z., Chatal J.F.

H3 A new method for labeling proteins with Technetium-99m. 360
Mahmood A., Delmon-Moingeon L.I., Limpa-Amara N., Davison A., Jones A.G.

H4 A new chelating heterodifunctional Phosphorus-Nitrogen ligand for radiolabeling of proteins. 362
Singh P., Volkert W.A., Ketring A.R., Troutner D.E., Katti K., Katti K.V.

H5 Tc-99m labeled Sandostatin: Preparation and preliminary evaluation. 365
Thakur M.L., Eshbach J., Wilder S., John E., McDevitt M.R.

H6 Copper-labeled antibodies for PET Imaging. 368
Anderson C.J., Schwarz S.W., Rocque P.A., Connett J.M., Guo L.W., Philpott G.W., Zinn K.R., Meares C.F., Welch M.J.

H7 Hydrolytic NHS-Ring opening during BAT-ligand conjugation with IgG. 370
Eisenhut M., Lehmann W.D.

H8 Receptor imaging with radiolabelled Peptides - Successful imaging of kidney and lung receptors with ^{123}I and ^{111}In-labelled Atrial Natriuretic Factor. 373
Flanagan R.J., Hogan K.T., Dufour J.M., Tartaglia D., Charleson F.P., Limoges R., Willenbrock R.W., Lambert R., Tremblay J., Bavaria G., Langlois Y., Hamet P.

H9 Synthesis of 2-(p-SCN-benzyl)-*trans*-Cyclohexyl-DTPA for α-Particle mediated radioimmunotherapy. 375
Brechbiel M.W., Pippin C.G., Mirzadeh S., Wu C., McMurry T.J., Gansow O.A., Colcher D., Melenic D., Roselli M., Huneke R., Strand M.

H10 Radioiodination of proteins using *N*-Succinimidyl-4-Hydroxy-3-Iodobenzoate. 378
Vaidyanathan G., Affleck D.J., Zalutsky M.R.

Présentation des affiches / *Poster presentation*

H11 Synthesis, characterization and evaluation of two new polyaminocarboxylates for linking Indium-111 to monoclonal antibodies. 381
Subramanian R., Colony J., Shaban S., McCabe R.P., Hanna M.G.

H12 Re-186 labeled antibodies: preparation and evaluation. 383
John E., Thakur M.L., DeFulvio J., McDevitt M.R., Wilder S.

H13 Synthesis and characterization of radiolabelled conjugates of human transferrin and IgG and TNT-1-F(ab')$_2$ fragments. 385
McDevitt M.R., Thakur M.L.

H14 Production and evaluation of Sc-47 for radioimmunotherapy. 388
Mausner L.F., Kolsky K.L., Mease R.C., Chinol M., Meinken G.E., Straub R.F., Pietrelli L., Steplewski Z., Srivastava S.C.

H15 Stabilization of ester bond in plasma to enhance target radioactivity delivery by antibody conjugated with metallic radionuclide through metabolizable ester linkage. 391
Arano Y., Inoue T., Mukai T., Taoka Y., Hosono M., Sakahara H., Konishi J., Yokoyama A.

H16 Radiosynthesis of Technetium-99m labeled human very-low density lipoprotein for scintigraphic study of lipoprotein receptor activity in vivo. 393
Moerlein S.M., Yahng C.S., Welch M.J.

H17 Approaches to monoclonal antibody labeling by use of metallic radionuclides. 396
Ruser G., Koch P., Kaden T., Paganelli G., Mäcke H.

H18 Site-specific modification of anti-CEA Fab'-fragments with chain-terminal chelating polymers: formation of reducible and non-reducible bonds. 397
Slinkin M., Curtet C., Faivre-Chauvet A., Gestin J.F., Chatal J.F.

H19 Radioactive labeled photosensitizers for tumor diagnostic and photodynamic therapy (PDT). 398
Sinn H., Graschew G., Friedrich E., Schlag P., Maier-Borst W.

H20 Direct ^{99m}Tc labeling of monoclonal antibodies (MoAb): Chemistry and biodistribution studies of two Technetium cores : ^{99m}Technetium-Oxo-MoAb (^{99m}TcO-MoAb) ^{99m}Tc-Nitrido-MoAb (^{99m}TcN-MoAb). 400
Garron J.Y., Moinereau M., Pasqualini R., Lamy M., Lecayon M., Saccavini J.C.

H21 A simple chromatographic method to determine by-products in labeling DTPA chelate monoclonal antibodies with (^{111}In)Indium. 402
Capillon Ph., Guerreau D., Garron J.Y., Pasqualini R.

H22 Evaluation of a direct method for Technetium labeling intact and F(ab')$_2$ 1A3 an anticolorectal monoclonal antibody. 404
Schwarz S.W., Rocque P.A., Anderson C.J., Welch M.J., Connett J.M., Philpott G.W.

I - COMPLEXES METALLIQUES / *METAL COMPLEXES*

Présidents de séance / *Chairpersons:* M.L. THAKUR - S.M. MOERLEIN

14:00 - 15:30 **Présentations orales / *Oral presentations***

I 1 First examples of heteroatomic chelation of ReO^-_4/$^{188}ReO^-_4$/$^{99m}TcO^-_4$ and $PdCl^{2-}_4$/$^{109}PdCl^{2-}_4$ with a phosphine-phosphineoxide (or a phosphinimine) bridged bifunctional system. 407
Katti K.V., Singh P.R., Katti K.K., Kopicka K., Barnes C.E., Volkert W.A., Ketring A.R.

I 2 Synthesis and evaluation of 4-Isothiocyanato- and 4-Bromoacetamido-Cyclohexyl EDTA (4-ICE and 4-BACE) as bifunctional chelating agents. 410
Mease R.C., Meinken G.E., Mausner L.F., Chinol M., Kolsky K.L., Straub R., Chatal J.F., Steplewski Z., Srivastava S.C.

I 3 Cationic Gallium(III) Schiff-base complexes that are retained in myocardium: Potential agents for imaging the heart with Gallium-68 and PET. 413
Tsang B.W., Mathias C.J., Green M.A.

I 4 New ligands for the formation of highly stable complexes of trivalent metal ions. 416
Martell A.E., Sun Y., Motekaitis R.J., Welch M.J.

I 5 ^{99m}Tc and ^{153}Sm labeling and biodistribution in rats of two new cyclic tetraphosphonates: 1,4,8,11-tetraazacyclodecane-N,N',N",N" tetramethylene phosphonic acid (TTMP) and 1,2,4,5-Benzenetetra-methylene phosphonic acid (BTMP). 418
Besnard M., Mollier H., Vincens M., Comazzi V., Lecayon M., Cohen Y., Pasqualini R.

I 6 Synthesis of ^{67}Ga-Deferoxamine-Digoxin bifunctional conjugate. 420
Fujibayashi Y., Takemura Y., Taniuchi H., Konishi J., Yokoyama A.

I 7 A Gallium labelled Desferrioxamine/Somatostatin analogue (SDZ 216-927). 422
Smith-Jones P., Stolz B., Albert R., Reist H., Bruns C., Mäcke H.

I 8 Structure and chemical characteristics of neutral Rhenium Diamine Dithiol (DADT) complexes. 424
Jackson T.W., Kojima M., Lambrecht R.M.

I 9 A Gallium-68 labeled chemotactic peptide analogue for imaging focal sites of bacterial infection by PET. 426
Moerlein S.M., Welch M.J., Hotchkiss R.M., Yahng C.S., Fischman A.J., Strauss H.W., Rubin R.H.

I 10 Mapping MRNAS for Histone 4 and NMDA in pig and human brain with In-111 labeled anti-sense oligonucleotides by in-situ hybridization. 428
Dewanjee M.K., Ghafouripour A.K., Werner R.K., Dietrich W.D., Gupta R., Glenn S., Serafini A.N., Sfakianakis G.N.

Présentation des affiches / *Poster presentation*

I 11 The stability of ^{90}Y-protein-complexes. 430
Schomäcker K., Környei J., Jantsch K., Shukla S.K., Limouris G.

I 12 New tumour-affine radioactive Yttrium compounds. 431
Schomäcker K., Franke W.G., Shukla S.K., Limouris G., Beyer G.J.

I 13 Preparation of bone tumor treatment agent of ^{90}Y-EDTMP. 432
Yang Z., Jin X., Yu H., Bai S.

I 14 Investigation of dialkyl Gallium(III) complexes as potential radiopharmaceuticals. 434
Coggin D.A.K., Mathias C.J., Green M.A.

I 15 The chemical fate of ^{212}Bi-DOTA formed by ß$^-$ decay of aqueous ^{212}Pb(DOTA)$^{2-}$. 437
Mirzadeh S., Kumar K., Gansow O.A.

I 16 Preparation of chromatographically and electrophoretically pure tumour-affine Gallium-67 species in aqueous solution for tumour detection. 440
Shukla S.K., Cipriani C., Argiro G., Tarantino U., Hani S., Baziotis N., Kateveni-Baziotis D., Limouris G., Cristalli M., Boccardi F., Atzei G.

I 17 The feasibility of ^{45}Ti-labelled chemotherapeutics, a study to produce [^{45}Ti]$TiCl_4$ and 441
^{45}Ti-labelled Budotitane.
Oberdorfer F., Keppler B.K., Zhou Y., Helus F., Maier-Borst W.

J - PRODUCTION DE RADIOISOTOPES / *RADIOISOTOPE PRODUCTION*

Présidents de séance / *Chairpersons:* W. MAIER-BORST - T.J. RUTH

16:00 - 17:30 **Présentations orales / *Oral presentations***

J1 Production of ^{208,209,210}At via ^{209}Bi(^{3}He, xn) processes. 443
Szelecsenyi F., Szucs Z., Solin O., Bergman J., Heselius S.J.

J2 Production of Bromine-75. Dosimetric rehabilitation of this PET tracer. 445
Brihaye Cl., Guillaume M., Trumper J., Depresseux J.C., Comar D.

J3 Cyclotron production of high-purity Tc-94m by *in situ* sublimation. 447
Nickles R.J., Christian B.T., Nunn A.D., Stone C.K.

J4 New nuclear data relevant to the production of the positron emitting radioisotope ^{86}Y. 449
Rösch F., Qaim S.M., Stöcklin G.

J5 A computer-controlled automated system for the production of high-purity ^{67}Ga and its chemical quality control by anodic stripping voltammetry. 451
Van den Winkel P., De Vis L., Coolsaet H., Van den Bossche C., Brits G., Van Daele F.

J6 Production of no-carrier-added [^{15}O]CO and [^{15}O]CO_2. 454
Iwata R., Ido T.

J7 A versatile system for single-breath inhalation or rebreathing of gases labeled with O-15, F-18, or C-11. 456
Wagner R., Arenz W., Richerzhagen N., Wienhard K.

J8 An advanced system for the administration of ^{15}O-Water. 459
Matzke K.H., Meyer G.J., Hundeshagen H.

J9 Proton irradiation of dilute aqueous ethanol for In-Target production of [^{13}N]Ammonia: studies on the fate of ethanol. 461
Ferrieri R.A., MacDonald K., Schlyer D.J., Wolf A.P.

J10 Production of ^{73}Se by proton irradiation of Cu_3 as target alloy. 464
De F. Santos D., Weinreich R.

Présentation des affiches / *Poster presentation*

J11 Preparation of ^{90}Sr-^{90}Y generator. 465
Jin X., Yu H., Zhang J., Zhang P., Lin Q.

J12 ^{113}Sn/^{113m}In generators - a study of their performance and quality. 467
Rakias F., Bodor M., Gerse J.

J13 Xenon-127 production in a reactor for medical applications. 468
Vereshagin Yu.I., Prusakov V.N., Yashin A.F.

J14 The Sr-82 cylotron production for medical purposes. Method. Experimental results. 469
Vereshagin Yu.I., Zagryadskiy V.A., Prusakov V.N.

J15 Use of vertical proton beam target for short-lived radionuclide production. 470
Tchuev V.I., Derevyanko E.P., Ekaeva I.V., Isotov V.G., Katunina T.A., Klebanov M.N., Larionov L.S., Marchenkov N.S.

J16 The ^{194}Os/^{194}Ir generator-production and purification of ^{194}OS. 471
Mirzadeh S., Rice D.E., Callahan A.P., Knapp F.F.

J17 Spontaneous electrochemical separation of carrier-free ^{64}Cu and ^{67}Cu from Zn targets. 474
Mirzadeh S., Rice D.E., Knapp F.F.

J18 Production and recovery of non carrier added ^{76}Br, ^{77}Br suitable for labelling of monoclonal antibodies. 477
Mertens J., Hermanne A., Terriere D., Lambert F.

J19 Production of ^{38}K at a low energy cyclotron. 478
Qaim S.M., Tarkanyi F., Kovacs Z., Stöcklin G.

J20 Cerium-134/Lanthanum-134, a new radionuclide generator system for positron emission tomography. 480
Zweit J., Goodall R., Babich J.W., Sharma H.L., Ott R.J.

J21 Gold-199: A potential radionuclide for diagnostic purposes. 483
Bonardi M., Gallorini M., Groppi F., Sanvito G.

VENDREDI 10 AVRIL 1992 / FRIDAY 10th APRIL 1992

K - CHIMIE DES PRODUITS RADIOPHARMACEUTIQUES ^{11}C, ^{18}F ET ^{123}I
^{11}C, ^{18}F AND ^{123}I - RADIOPHARMACEUTICAL CHEMISTRY

Présidents de séance / *Chairpersons:* W. VAALBURG - J. FOWLER

9:00 - 10:30 **Présentations orales / *Oral presentations***

K1 [^{18}F]Vesamicol derivatives for *in vivo* evaluation as tracers for cholinergic synaptic vesicles. 486
Rogers G., Stone-Elander S., Eriksson L., Ingvar M., Parsons S., Widen L.

K2 Efficient one-step synthesis of (-)-[^{18}F]Fluoroethoxy-Benzovesamicol (FEOBV). A new tracer for mapping cholinergic neurons in vivo. 487
Mulholland G.K., Jung Y.W., Sherman P.S., Pisani T.L., Kuhl D.E., Wieland D.M., Kilbourn M.R.

K3 Development of a radiotracer for mapping acetylcholinesterase in the brain in vivo. 488
Irie T., Fukushi K., Akimoto Y., Tamagami H., Nozaki T.

K4 Iodo-tomoxetine derivatives: selective ligands for serotonin reuptake sites. 490
Chumpradit S., Kung M.P., Brooks B.P., Szabo S.A., Panyachotipun C., Prapansiri V., Kung H.F.

K5 Carbon-11 labeled alpha-2 adrenergic receptor antagonist: synthesis of [^{11}C]WY26703 and its biodistribution in rodents. 493
Pleus R.C., Shiue C.Y., Shiue G.G., Rysavy J.A., Huang H., Frick M.P., Bylung D.B.

K6 [^{11}C]RX 821002 as a potential PET radioligand for central α_2 adrenoceptors. 495
Pike V.W., Hume S.P., Aigbirhio F., Turton D.R., Nutt D.J.

K7 Selective N.C.A. ^{11}C-labelling of Tramadol and its major metabolites for PET pharmacokinetics. 498
Gail R., Coenen H.H., Hamacher K., Stöcklin G.

K8 Fluorine-18 labeled BMY 14802: Synthesis and anatomical distribution in rodents. 501
Shiue C.Y., Bai L.Q., Shiue G.G., Rysavy J.A., Pleus R.C., Huang H., Frick M.P., Catt J.D., Yevich J.P.

K9 Comparison of *S*-[^{11}C]CGP 12177 metabolism in rat, dog and man using solid phase extraction and HPLC. 504
Luthra S.K., Osman S., Steel C.J., Law M.P., Rhodes C.G., Vaja V., Ahier R., Brady F., Waters S.L., De Silva R., Hughes J.M.B., Camici P.G.

K10 Synthesis, labeling and experimental study of new ^{125}I-labeled compounds. Potential application for diagnosis and treatment of malignant melanoma in nuclear medicine. 506
Moreau M.F., Madelmont J.C., Labarre P., Papon J., Bayle M., Michelot J., Mauclaire L., Veyre A.

Présentation des affiches / *Poster presentation*

K11 Measurement of [Methyl-^{11}C]Thymidine and ^{11}C-metabolites in human plasma. 509
Goethals P., Coene M., Van Eijkeren M., Thierens B.

K12 Kinetic evaluation of 16α^{18}F]Fluoro-17ß-Estradiol as a ligand for in vivo estrogen receptor binding in the rat brain. 513
Moresco R.M., Casati R., Carpinelli A., Todde S., Lucignani G., Colombo F., Fazio F.

K13 Robotic determination of discrete time input functions for quantitative PET: measurement of plasma radioactivity concentration. 514
Alexoff D.L., Gatley S.J., Wolf A.P., Fowler J.S.

K14 Measurement of low-levels of PET nuclides in plasma metabolite assays: use of a modern liquid scintillation counter (LSC). 516
Gatley S.J., MacNabb C.

K15 An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [^{11}C]-L-deprenyl; [^{11}C]diprenorphine; [^{11}C]flumazenil; [^{11}C]raclopride; and [^{11}C]Scherring 23390. 518
Luthra S.K., Osman S., Turton D.R., Vaja V., Dowsett K., Brady F.

K16 A practical synthesis of 5-[^{18}F]Fluorouracil using HPLC and a study of its metabolic profile in rats. 521
Brown G.D., Khan H.R., Steel C.J., Luthra S.K., Osman S., Hume S.P., Tilsley D.W.O., Waters S.L., Poole K.G., Price P., Brady F.

K17 [^{18}F]Altanserine: a short synthesis of the nitro-precursor and preliminary metabolic studies in rat. 523
Monclus M., Biver F., Goldman S., Luxen A.

K18 Radiosynthesis and baboon PET experiments of [^{11}C]Triazolam. 525
Le Breton C., Bottlaender M., Crouzel C., Varastet M., Sitbon R., Mazière B., Mazière M.

K19 Comparative metabolism of enantiomers of 5- and 6-Fluoro-DOPA in aggregating brain cell cultures. 528
Wiese C., Cogoli-Greuter M., Argentini M., Weinreich R., Winterhalter K.H.

K20 One step determination of ionisation constant and lipophilicity (Log P) of radiopharmaceuticals using the shake-flask method. 531
Loc'h C., Mazière B.

K21 Preparation of [123-I]Iododenopamine: a potential radiotracer for myocardial ß adrenergic receptor studies. 533
Bertaux M., Brutesco C., Loc'h C., Valette H., Mazière B.

K22 Measurement of 18F-Fluoro-DOPA metabolism in plasma using radio-TLC analysis. 535
Loc'h C., Wang R.F., Mazière B.

L - PRODUITS RADIOPHARMACEUTIQUES POUR L'ETUDE DU METABOLISME ET LA MESURE DE DEBIT / *RADIOPHARMACEUTICALS FOR METABOLISM AND FLOW MEASUREMENTS*

Présidents de séance / *Chairpersons:* D.J. SILVESTER - C. HALLDIN

11:00 - 12:30 **Présentations orales / *Oral presentations***

L1 A radiosynthesis of 6-[C-11]-α-D-Glucose from [C-11]Methyl Iodide. 537
Grierson J.R., Biskupiak J.E., Link J.M., Courter J.H., Krohn K.A.

L2 1-[^{11}C]Labeled polyhomoallylic fatty acids: Phospholipid metabolic tracers for the brain. 539
Channing M.A., Freed L.M., Wakabayashi S., Carson R.E., Simpson N., Dunn B.B., Eckelman W.C., Rapoport S.I.

L3 Efficient radiosynthesis of [^{18}F]-Fluoromisonidazole suitable for routine PET. 541
Lim J.L., Berridge M.S.

L4 Fluorine-18 labeled analogs of Meta-Iodobenzylguanidine. 544
Garg P.K., Garg S., Welsh P.C., Zalutsky M.R.

L5 [^{11}C]-2-Methoxy-Phenyl-Metyrapone for PET. 547
Zolle I., Halldin C., Yu J., Berger M.

L6 Synthesis and evaluation of ^{11}C- and 18F-labeled purine nucleosides as a tracer for adenosine transport and metabolism. 550
Fukushi K., Irie T., Suzuki K., Fukuda H.

L7 Synthesis and *in vivo* behavior of F-18 labeled analog of D-Talose: 2-Deoxy-2-[^{18}F]Fluoro-D-Talose. 552
Haradahira T., Kato A., Maeda M., Kanazawa Y., Yamada M., Torii Y., Ichiya Y., Masuda K.

L8 New results concerning the metabolism of ω-(4'-Iodophenyl)pentadecanoic acid (IPPA). 555
Eisenhut M., Lehmann W.D., Sütterle A.

L9 Preparation and in vivo comparison of ^{62}Cu-labeled blood-pool agents. 558
Anderson C.J., Welch M.J., Weinheimer C.J., Bergmann S.R.

L10 Retention mechanism of Cu-62-PTSM in the brain: irreversible reduction of Cu-PTSM by mitochondrial enzyme. 560
Fujibayashi Y., Wada K., Taniuchi H., Yonekura Y., Konishi J., Yokoyama A.

Présentation des affiches / *Poster presentation*

L11 Synthesis of 2-[^{18}F]FDG using tetraalkylammonium bicarbonates. 562
Johnson B.F., Maylotte D.H., Sabourin C.L., Finn R., Kothari P.

L12 Development and validation of a solvent extraction technique for determination of Cu-PTSM in blood. 565
Green M.A., Mathias C.J.

L13 Synthesis of fluorine-18 labeled 4-Fluoro-4-Deoxy-D-Glucose as a potential brain, heart and tumor imaging agent. 568
Goodman M.M., Kabalka G.W., Longford C.P.D.

L14 Fluorination via cyclic sulfamidates: High yield stereospecific synthesis of ß-[F-18]Fluoromethamphetamines. 570
Van Dort M.E., Jung Y.W., Kilbourn M.R., Wieland D.M.

L15 A new method for the synthesis and Fluorine-18 labelling of 2-Deoxy-2-Fluoro-D-Galactose. 572
Edwards W.B., Dence C.S., Welch M.J.

L16 An improved synthesis of 1-[^{11}C]-D-Glucose. 574
Dence C.S., Welch M.J.

L17 Fleroxacin. A quinolone antibacterial agent, labeling with Fluorine-18 for pharmacokinetic studies. 576
Livni E., Fischman A.J., Strauss H.W., Rubin R.H., Liu Y.Y., Thom E., Cleeland R.

L18 A modified and improved system for synthesis of ^{18}F-2-Deoxy-2-Fluoro-D-Glucose (2-FDG) based on the resin exchanged method. 578
Najafi A., Peterson A.

L19 Synthesis of labelled Thymidine using enzyme based hollow fiber membrane bioreactors. 581
Hughes J., Jay M.

L20 Synthesis of radiolabelled ω-iodoalkyl glucosides. 584
Bignan G., Mathieu J.P., Mauclaire L., Morin C., Vidal M.

L21 Labelling of D-glucosamine in position 1 with [^{11}C]Cyanide. 586
Thorell J.O., Stone-Elander S., Von Holst H.

L22 The preparation of an ^{11}C-labelled 5-lipoxygenase product, 5(S)-Hydroxy-6(R)-(N-1-[^{11}C]Acetyl) Cysteinyl-7,9-Trans-11,14-Cis-Eicosatetraenoic acid. 587
Oberdorfer F., Siegel T., Guhlmann A., Keppler D., Maier-Borst W.

12:30 - 13:00 Clôture du Symposium / *Closing remarks*

AUTHOR INDEX 589